Home | Phase II-III study to evaluate the safety and immunogenicity of the pneumococcal vaccine candidate VCN11 in adult participants aged 50 to 74 years.

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials Phase II-III study to evaluate the safety and immunogenicity of the pneumococcal vaccine candidate VCN11 in adult participants aged 50 to 74 years. has only one revision
RevisionStatus
Saved 27/12/2024 - 11:43am by Gladyscurrent revision (published)
Equipo de Trabajo del RPCEC | CENCEC - MINSAP
rpcec@cencec.sld.cu
Calle 5ta A Edificio CECMED-CENCEC 2do piso e/ 60 y 62 Miramar, Playa.CP 11300. La Habana, Cuba
Telef: (537) 216-4126 | (537) 216-4212 | (537) 216-4218.
Copyright © 2014-2022 All Rights Reserved.